Influence of laropiprant, a selective prostaglandin D2 receptor 1 antagonist, on the pharmacokinetics and pharmacodynamics of warfarin

American Journal of Therapeutics

Volumn 16, Issue 3, 2009, Pages 215-223

  Schwartz, Jules I ^a   Liu, Fang ^a   Stroh, Mark ^a   Gipson, Adrianna ^a   Johnson Levonas, Amy O ^a   Lasseter, Kenneth C ^b   Lai, Eseng ^a   Wagner, John A ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

^b Clinical Pharmacology of Miami   (United States)

Author keywords

Laropiprant; Pharmacodynamics; Pharmacokinetics; Warfarin

Indexed keywords

LAROPIPRANT; WARFARIN;

ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG HALF LIFE; FEMALE; HEADACHE; HUMAN; HUMAN EXPERIMENT; INTERNATIONAL NORMALIZED RATIO; MALE; MAXIMUM PLASMA CONCENTRATION; NORMAL HUMAN; OPEN STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SINGLE DRUG DOSE; STOMACH PAIN; TIME TO MAXIMUM PLASMA CONCENTRATION; TOOTH PAIN;

ADULT; ANTICOAGULANTS; AREA UNDER CURVE; CROSS-OVER STUDIES; DRUG INTERACTIONS; FEMALE; HUMANS; INDOLES; INTERNATIONAL NORMALIZED RATIO; MALE; MIDDLE AGED; RECEPTORS, IMMUNOLOGIC; RECEPTORS, PROSTAGLANDIN; STEREOISOMERISM; WARFARIN;

EID: 67249129221     PISSN: 10752765     EISSN: None     Source Type: Journal    
DOI: 10.1097/MJT.0b013e31818f9c68     Document Type: Article

References (44)

1. Carlson LA. Nicotinic acid: the broad-spectrum lipid drug. A 50th anniversary review. J Intern Med. 2005;258: 94-114.
2. The Coronary Drug Project Research Group. Clofibrate and niacin in coronary heart disease. JAMA. 1975;231: 360-381.
3. Brown BG, Zhao XQ, Chait A, et al. Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease. N Engl J Med. 2001;345: 1583-1592.
4. Taylor AJ, Sullenberger LE, Lee HJ, et al. Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol (ARBITER) 2: a double-blind, placebo-controlled study of extended-release niacin on atherosclerosis progression in secondary prevention patients treated with statins. Circulation. 2004;110:3512-3517.
5. Capuzzi DM, Morgan JM, Brusco OA Jr, et al. Niacin dosing: relationship to benefits and adverse effects. Curr Atheroscler Rep. 2000;2:64-71.
6. Birjmohun RS, Hutten BA, Kastelein JJ, et al. Increasing HDL cholesterol with extended-release nicotinic acid: from promise to practice. Neth J Med. 2004;62:229-234.
7. Morgan JM, Capuzzi DM, Guyton JR. A new extended-release niacin (Niaspan): efficacy, tolerability, and safety in hypercholesterolemic patients. Am J Cardiol. 1998;82 (12A):29U-34U.
8. Mills E, Prousky J, Raskin G, et al. The safety of over-the-counter niacin. A randomized placebo-controlled trial [ISRCTN18054903]. BMC Clin Pharmacol. 2003;3:4.
9. Morrow JD, Parsons WG III, Roberts LJ. Release of markedly increased quantities of prostaglandin D2 in vivo in humans following the administration of nicotinic acid. Prostaglandins. 1989;38:263-274.
10. Morrow JD, Awad JA, Oates JA, et al. Identification of skin as a major site of prostaglandin D2 release following oral administration of niacin in humans. J Invest Dermatol. 1992;98:812-815.
11. Phillips WS, Lightman SL. Is cutaneous flushing prostaglandin mediated? Lancet. 1981;1:754-756.
12. Wilkin JK, Fortner G, Reinhardt LA, et al. Prostaglandins and nicotinate-provoked increase in cutaneous blood flow. Clin Pharmacol Ther. 1985;38:273-277.
13. Benyo Z, Gille A, Bennett CL, et al. Nicotinic acid-induced flushing is mediated by activation of epidermal Langerhans cells. Mol Pharmacol. 2006;70:1844-1849.
14. Maciejewski-Lenoir D, Richman JG, Hakak Y, et al. Langerhans cells release prostaglandin D2 in response to nicotinic acid. J Invest Dermatol. 2006;126: 2637-2646.
15. Cheng K, Wu TJ, Wu KK, et al. Antagonism of the prostaglandin D2 receptor 1 suppresses nicotinic acid-induced vasodilation in mice and humans. Proc Natl Acad Sci U S A. 2006;103:6682-6687.
16. Chang SW, Reddy V, Pereira T, et al. The pharmacokinetics and disposition of MK-0524, a prostaglandin D2 receptor 1 antagonist, in rats, dogs and monkeys. Xenobiotica. 2007;37:514-533.
17. Lai E, De Lepeleire I, Crumley TM, et al. Suppression of niacin-induced vasodilation with an antagonist to prostaglandin D-2 receptor subtype 1. Clin Pharmacol Ther. 2007;81:849-857.
18. Levesque JF, Day SH, Chauret N, et al. Metabolic activation of indole-containing prostaglandin D2 receptor 1 antagonists: impacts of glutathione trapping and glucuronide conjugation on covalent binding. Bioorg Med Chem Lett. 2007;17:3038-3043.
19. Sturino CF, O'Neill G, Lachance N, et al. Discovery of a potent and selective prostaglandin D2 receptor antagonist, [(3R)-4-(4-chloro-benzyl)-7- fluoro-5-(methylsulfonyl)-1,2,3,4- tetrahydrocy clopenta[b]indol-3-yl]-acetic acid (MK-0524). J Med Chem. 2007;50:794-806.
20. Paolini JF, Mitchel YB, Reyes R, et al. Effects of laropiprant on nicotinic acid-induced flushing in patients with dyslipidemia. Am J Cardiol. 2008;101:625-630.
21. Dean BJ, Chang S, Silva Elipe MV, et al. Metabolism of MK-0524, a prostaglandin D2 receptor 1 antagonist, in microsomes and hepatocytes from preclinical species and humans. Drug Metab Dispos. 2007;35:283-292.
22. Karanam B, Madeira M, Bradley S, et al. Absorption, metabolism, and excretion of [(14)C]MK-0524, a prostaglandin D(2) receptor antagonist, in humans. Drug Metab Dispos. 2007;35:1196-1202.
23. Nicoll-Griffith DA, Seto C, Aubin Y, et al. In vitro biotransformations of the prostaglandin D2 (DP) antagonist MK-0524 and synthesis of metabolites. Bioorg Med Chem Lett. 2007;17:301-304.
24. Lai E, Wenning LA, Crumley TM, et al. Pharmacokinetics, pharmacodynamics, and safety of a prostaglandin D2 receptor antagonist. Clin Pharmacol Ther. 2008;83:840-847.
25. Hirsh J. Oral anticoagulant drugs. N Engl J Med. 1991;324: 1865-1875.
26. Kirkwood TB. Calibration of reference thromboplastins and standardisation of the prothrombin time ratio. Thromb Haemost. 1983;49:238-244.
27. Johnston M, Harrison L, Moffat K, et al. Reliability of the international normalized ratio for monitoring the induction phase of warfarin: comparison with the prothrombin time ratio. J Lab Clin Med. 1996;128:214-217.
28. Serlin MJ, Breckenridge AM. Drug interactions with warfarin. Drugs. 1983;25:610-620.
29. Freedman MD, Olatidoye AG. Clinically significant drug interactions with the oral anticoagulants. Drug Saf. 1994; 10:381-394.
30. th Edition). Chest. 2008;133:160S-198S.
31. Herman D, Locatelli I, Grabnar I, et al. Influence of CYP2C9 polymorphisms, demographic factors and concomitant drug therapy on warfarin metabolism and maintenance dose. Pharmacogenomics J. 2005;5:193-202.
32. Black DJ, Kunze KL, Wienkers LC, et al. Warfarin-fluconazole. II. A metabolically based drug interaction: in vivo studies. Drug Metab Dispos. 1996;24:422-428.
33. Rettie AE, Korzekwa KR, Kunze KL, et al. Hydroxylation of warfarin by human cDNA-expressed cytochrome P-450: a role for P-4502C9 in the etiology of (S)-warfarin-drug interactions. Chem Res Toxicol. 1992;5:54-59.
34. Kaminsky LS, Zhang ZY. Human P450 metabolism of warfarin. Pharmacol Ther. 1997;73:67-74.
35. Trager WF, Lewis RJ, Garland WA. Mass spectral analysis in the identification of human metabolites of warfarin. J Med Chem. 1970;13:1196-1204.
36. Ufer M. Comparative pharmacokinetics of vitamin K antagonists: warfarin, phenprocoumon and acenocoumarol. Clin Pharmacokinet. 2005;44:1227-1246.
37. Maccubbin DL, Sirah W, Betteridge A. Lipid-altering efficacy and tolerability profile of extended release niacin/laropiprant in patients with primary hypercholesterolemia or mixed hyperlipidemia. Eur Heart J. 2007; 28:108.
38. Van Hecken A, Depre M, Verbesselt R, et al. Effect of montelukast on the pharmacokinetics and pharmacodynamics of warfarin in healthy volunteers. J Clin Pharmacol. 1999;39:495-500.
39. Anderson DM, Shelley S, Crick N, et al. No effect of the novel antidiabetic agent nateglinide on the pharmacokinetics and anticoagulant properties of warfarin in healthy volunteers. J Clin Pharmacol. 2002;42:1358-1365.
40. He YL, Sabo R, Riviere GJ, et al. Effect of the novel oral dipeptidyl peptidase IV inhibitor vildagliptin on the pharmacokinetics and pharmacodynamics of warfarin in healthy subjects. Curr Med Res Opin. 2007;23:1131-1138.
41. Ouellet D, Bramson C, Carvajal-Gonzalez S, et al. Effects of lasofoxifene on the pharmacokinetics and pharmacodynamics of single-dose warfarin. Br J Clin Pharmacol. 2006;61:741-745.
42. Soon D, Kothare PA, Linnebjerg H, et al. Effect of exenatide on the pharmacokinetics and pharmacodynamics of warfarin in healthy Asian men. J Clin Pharmacol. 2006;46:1179-1187.
43. Schwartz JI, Bugianesi KJ, Ebel DL, et al. The effect of rofecoxib on the pharmacodynamics and pharmacokinetics of warfarin. Clin Pharmacol Ther. 2000;68: 626-636.
44. Zhou H, Patat A, Parks V, et al. Absence of a pharmacokinetic interaction between etanercept and warfarin. J Clin Pharmacol. 2004;44:543-550.